MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

Date 2026-05-29

MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic

diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-

generation therapeutic for obesity. 

 

MEDI&GENE's discovery platform is designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight

maintenance, lean mass maintenance, and durability of desired metabolic effects.

 

Under the agreement, Lilly ExploR&D will bring Lilly's expertise in molecule engineering and development to a MEDI&GENE asset,

with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to

empower biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

 

"We are excited to work with Lilly to advance a next-generation obesity drug candidate. We believe this collaboration will accelerate

clinical development and help bring differentiated solutions to patients with obesity," said Min-Jeong Shin, CEO of MEDI&GENE.

 

Founded in 2021, MEDI&GENE has established a discovery engine centered on metabolic and obesity-related pathways and has

identified multiple innovative candidates through its mechanistic platform. The company expects that the collaboration will support the

continued advancement of its research initiatives in next-generation obesity therapeutics.